Menarini focuses MEN2312 Introduction
Design by Insilico’s R&D team with the assistance of its endtoend pharmaceutical generation AI
platform, MEN2312 can block endocrine receptors (ER) at the transcriptional level, giving it the
potential to overcome resistance to endocrine palau email list 100000 contact leads therapy due to mutations or ligandindependent
constitutive activation of ER. In preclinical studies, this molecule has been shown to have a potent
inhibitory effect on KAT6 in a variety of CDX and PDX models, with good efficacy and high safety.
About Menarini Group
Menarini Group is a leading international pharmaceutical and diagnostics company with revenues in
excess of US$ 4.7 billion and over 17,000 employees. In areas of unmet therapeutic ne, including
cardiology, oncology, respiratory micine, gastroenterology, infectious diseases, diabetes, inflammation
and analgesia. Menarini has 18 production sites and 9 R&D centers, and its products are sold in 140 countries around the world. For more information, please visit Menarini.com.
About Stemline Therapeutics Inc.
Stemline Therapeutics, Inc. (“Stemline”), a wholly own subsidiary of Menarini Group, is a
commercialstage biopharmaceutical company the 9 best moonmail alternatives to accelerate email marketing conversions focus on the development and commercialization of
novel oncology therapeutics. Stemline launches ORSERDU® (elacestrant) in the US and EU, an oral
endocrine therapy for the treatment of patients with estrogen receptor (ER)positive, human epidermal growth factor receptor 2 (HER2)negative.
ESR1mutatadvance or metastatic breast cancer whose disease has progress after
At least one line of endocrine therapy. Stemline also launch ELZONRIS® (tagraxofusperzs) in the U.S.
and Europe, an innovative target therapy for CD123, for the treatment of patients with blastic
plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive blood cancer. It is the only approv
treatment for BPDCN in the U.S. and EU to date. Stemline philippines numbers also commercializes NEXPOVIO® (selinexor), an XPO1 inhibitor for the treatment of multiple myeloma, in Europe. In addition, Stemline has a broad pipeline of small molecule and biologic clinical products in various stages of development for the treatment of a variety of solid and blood cancers Menarini focuses.